Evidence map›Paper›PMID 27979597›Full record

ArticleKidney international2017

Inhibition of TRPC6 channels ameliorates renal fibrosis and contributes to renal protection by soluble klotho.

Yueh-Lin Wu, Jian Xie, Sung-Wan An, Noelynn Oliver, Nestor X Barrezueta, Mei-Hsiang Lin, Lutz Birnbaumer, Chou-Long Huang

Open access · greenAbstract read
In one paragraph

Article in Kidney international, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 63 papers.

0numbers the graph read from it
0cells of the map it votes in
63citing papers in PubMed
8.7field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

63 citing papers in PubMed, 104 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Calcium signalling and transport in the kidney.Nature reviews. Nephrology · 2024
    Review
  8. Article
  9. Article
  10. Roles of TRP and PIEZO receptors in autoimmune diseases.Expert reviews in molecular medicine · 2024
    Review
  11. Article
  12. Article
  13. A Putative Role for TRPC6 in Immune-Mediated Kidney Injury.International journal of molecular sciences · 2023
    Review
  14. Article
  15. Article
  16. Review
  17. Article
  18. Review
  19. Article
  20. Review

3 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors at 6 institutions in 3 countries.

Yueh-Lin WuDivision of Nephrology, Department of Medicine, University of Texas Southwestern Medical Center, Dallas, Texas, USA; Division of Nephrology, Department of Internal Medicine, Taipei Medical University Hospital, Taipei, Taiwan; Division of Nephrology, Department of Internal Medicine, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan; Graduate Institute of Clinical Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan.
Jian XieDivision of Nephrology, Department of Medicine, University of Texas Southwestern Medical Center, Dallas, Texas, USA.
Sung-Wan AnDivision of Nephrology, Department of Medicine, University of Texas Southwestern Medical Center, Dallas, Texas, USA.
Noelynn OliverCardioMetabolic Diseases Research, Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, Connecticut, USA.
Nestor X BarrezuetaCardioMetabolic Diseases Research, Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, Connecticut, USA.
Mei-Hsiang LinSchool of Pharmacy, College of Pharmacy, Taipei Medical University, Taipei, Taiwan.
Lutz BirnbaumerLaboratory of Neurobiology, National Institute of Environmental Health Sciences, Research Triangle Park, North Carolina, USA; Institute of Biomedical Research (BIOMED), Catholic University of Argentina, Buenos Aires, Argentina.
Chou-Long HuangDivision of Nephrology, Department of Medicine, University of Texas Southwestern Medical Center, Dallas, Texas, USA. Electronic address: Chou-Long.Huang@UTSouthwestern.edu.
Boehringer Ingelheim (United States) · USThe University of Texas Southwestern Medical Center · USPontificia Universidad Católica Argentina · ARSouthwestern Medical Center · USTaipei Medical University · TWTaipei Medical University Hospital · TW

Funding

UT Southwestern O'Brien Kidney Research Core CenterP30DK079328 · NIDDK · UT SOUTHWESTERN MEDICAL CENTER · PI MOE, ORSON W · 2007 to 2021
$16.9M
Klotho and Chronic Kidney DiseaseR01DK100605 · NIDDK · UT SOUTHWESTERN MEDICAL CENTER · PI HUANG, CHOU-LONG · 2014 to 2023
$3.5M
Transmembrane Signaling Mechanisms Involving TRP ChannelsZ01ES101684 · NIEHS · NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES · PI BIRNBAUMER, LUTZ · 2003 to 2008
$2.1M
Regulation of Renal Calcium Transport in Health and DiseaseR01DK109887 · NIDDK · UT SOUTHWESTERN MEDICAL CENTER · PI HUANG, CHOU-LONG · 2016 to 2020
$1.8M
Regulation of renal calcium transportR01DK085726 · NIDDK · UT SOUTHWESTERN MEDICAL CENTER · PI HUANG, CHOU-LONG · 2010 to 2014
$1.7M
Intramural NIH HHS Z01 ES101684NIDDK NIH HHS P30 DK079328NIDDK NIH HHS R01 DK085726NIDDK NIH HHS R01 DK100605NIDDK NIH HHS R01 DK109887
6 · The paper itself

Abstract

Fibrosis is an exaggerated form of tissue repair that occurs with serious damage or repetitive injury and ultimately leads to organ failure due to the excessive scarring. Increased calcium ion entry through the TRPC6 channel has been associated with the pathogenesis of heart and glomerular diseases, but its role in renal interstitial fibrosis is unknown. We studied this by deletion of Trpc6 in mice and found it decreased unilateral ureteral obstruction-induced interstitial fibrosis and blunted increased mRNA expression of fibrosis-related genes in the ureteral obstructed kidney relative to that in the kidney of wild-type mice. Administration of BTP2, a pyrazol derivative known to inhibit function of several TRPC channels, also ameliorated obstruction-induced renal fibrosis and gene expression in wild-type mice. BTP2 inhibited carbachol-activated TRPC3 and TRPC6 channel activities in HEK293 cells. Ureteral obstruction caused over a 10-fold increase in mRNA expression for TRPC3 as well as TRPC6 in the kidneys of obstructed relative to the sham-operated mice. The magnitude of protection against obstruction-induced fibrosis in Trpc3 and Trpc6 double knockout mice was not different from that in Trpc6 knockout mice. Klotho, a membrane and soluble protein predominantly produced in the kidney, is known to confer protection against renal fibrosis. Administration of soluble klotho significantly reduced obstruction-induced renal fibrosis in wild-type mice, but not in Trpc6 knockout mice, indicating that klotho and TRPC6 inhibition act in the same pathway to protect against obstruction-induced renal fibrosis. Thus klotho and TRPC6 may be pharmacologic targets for treating renal fibrosis.

Indexed as

AnilidesAnimalsCytoprotectionDisease Models, AnimalDose-Response Relationship, DrugFibrosisGene Expression RegulationGenetic Predisposition to DiseaseGlucuronidaseHEK293 CellsHumansKidneyKidney DiseasesKlotho ProteinsMaleMice, 129 Strain4-methyl-4'-(3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl)-1,2,3-thiadiazole-5-carboxanilideAnilidesGlucuronidaseKlotho ProteinsRNA, MessengerThiadiazolesTRPC3 cation channelTRPC6 Cation ChannelTrpc6 protein, mouseTRPC Cation ChannelsUrological AgentsBTP2fibrosisklothoTRPC3TRPC6UUO

Identifiers

PMID27979597
PMCPMC5357448
OpenAlexW2562909145

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.